In patients suffering from hard-to-manage lipid disorders, one administration of an experimental CRISPR treatment reduced LDL cholesterol and triglycerides by roughly half. These decreases persisted for a complete year, with the strongest dose bringing down LDL by 52.5% and triglycerides by 47.8%.
A Phase 1 clinical trial led by Cleveland Clinic produced the result, following 15 patients over one year to determine if the cholesterol and triglyceride reductions seen after two months persisted. Participants given the highest dose of CTX310 saw their LDL cholesterol fall by 52.5% from baseline, alongside a 47.8% decrease in triglycerides, after 12 months.
How CTX310 Works
The CRISPR editing system rides through the bloodstream inside CTX310, a single infusion, and lands within the liver. There it silences the gene labeled ANGPTL3, a controller of the fats carried by the blood. Shutting down this gene has been shown to lower LDL cholesterol and triglycerides, two factors linked to cardiovascular disease.
Prior to the infusion, patients were given corticosteroids and antihistamines. The study subjects were administered CTX310 at dose levels between 0.1 and 0.8 mg/kg. Safety was tracked throughout, alongside measurements of ANGPTL3, LDL cholesterol, and triglyceride levels.
| Measure | Highest dose, 12 months |
|---|---|
| LDL cholesterol reduction | 52.5% |
| Triglyceride reduction | 47.8% |
What the Trial Found
Switzerland’s CRISPR Therapeutics AG covered the cost of the trial, and Dr. Laffin’s institution has received research funding from that company. The results were presented at the 2026 European Society of Cardiology annual meeting and appeared in the New England Journal of Medicine at the same time.
The research found that “No serious adverse events related to the therapy were reported during the one-year follow-up.” That finding stands alongside the trial’s central numbers: LDL cholesterol down 52.5% and triglycerides down 47.8% at the highest dose after 12 months.
“Building upon the initial data presented in November 2025, the durability of the lipid-lowering effect was impressive,” said Cleveland Clinic cardiologist Luke Laffin, M.D., first author of the study. “It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment. We look forward to continuing to investigate this therapy in a larger number of patients.”
The Road Ahead
The research focused on just 15 subjects, and CTX310 is still being tested rather than used widely. After participants received treatment, they were watched for a full year. The scientists say they will keep following up on safety for an additional 15 years, matching what the FDA recommends for gene-editing treatments.
A simple design: one dose, a limited number of subjects, a year of observation, and a report made public. The statistics stand out, and the lack of any serious safety events over that period is worth noting.
A year after the reductions began, they were still being seen, with the highest dose dropping LDL by 52.5% and triglycerides by 47.8%. That result makes up the heart of the report, and it comes across as promising news for those whose lipid disorders do not respond to medicine. Whether it leads to more widespread use depends on the next round of testing, which the study team has already started planning.
The results are currently presented as originally reported. The persistence of the benefit was notable, and the safety record stayed free of adverse events throughout the entire year of observation. The remaining 15 years of tracking will offer further information.
Source material: “One CRISPR treatment cut “bad” cholesterol in half for a full year,” ScienceDaily.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.